You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Johnson and Johnson
Baxter
Boehringer Ingelheim
Merck

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,566,272

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,566,272 protect, and when does it expire?

Patent 9,566,272 protects JUBLIA and is included in one NDA.

This patent has twenty-one patent family members in fourteen countries.

Summary for Patent: 9,566,272
Title:Compositions and methods for treating diseases of the nail
Abstract: Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a mixture of the vehicle and the non-volatile solvent, and which composition is effective in treating a disorder of the nail or nail bed.
Inventor(s): Winckle; Gareth (Biot, FR), Fieldson; Gregory T. (Morgantown, WV)
Assignee: DOW PHARMACEUTICAL SCIENCES, INC. (Petaluma, CA)
Application Number:14/755,699
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,566,272
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 9,566,272

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch JUBLIA efinaconazole SOLUTION;TOPICAL 203567-001 Jun 6, 2014 RX Yes Yes   Start Trial   Start Trial TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,566,272

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 070083   Start Trial
Australia 2008343795   Start Trial
Australia 2013204596   Start Trial
Australia 2016277570   Start Trial
Brazil PI0822162   Start Trial
Canada 2706114   Start Trial
China 101909634   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Boehringer Ingelheim
McKinsey
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.